An experimental pill for leukemia has shown promise in early clinical trials — sending a third of patients with aggressive disease into complete remission.The drug — revumenib — was also credited with putting half of patients with acute myeloid leukemia (AML) into partial remission during phase one clinical trials.Dr Scott Armstrong, a blood expert at the Dana-Farber Cancer Institute in Boston, , who is running the trial, heralded the results as 'very encouraging'. But he said more research was needed to prove that the drug worked.
Load More
Load More